La Hnscc clinical trials

Explore recruiting la hnscc clinical trials.

Recruiting la hnscc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

La Hnscc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head and Neck squamous cell carcinoma (RADIAN)

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma

Greece, Portugal, Belgium, France, Spain, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

EORTC 2120-HNCG: Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck squamous cell carcinoma: a randomized phase II study (Ravina)

Italy, Slovenia, Germany, Netherlands, Belgium, Norway +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized Phase 2 trial of induction treatment of anti-PD-1 pucotenlimab and EGFR-ADC MRG003 or EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (LA-SCCHN).

France

Therapeutic exploratory (Phase II) EU CTIS Study details

La Hnscc trials by city

La Hnscc in Toronto La Hnscc in Vancouver La Hnscc in Montreal La Hnscc in Calgary La Hnscc in Edmonton La Hnscc in Ottawa La Hnscc in Winnipeg La Hnscc in Quebec City La Hnscc in Hamilton La Hnscc in Kitchener La Hnscc in London La Hnscc in Halifax La Hnscc in New York La Hnscc in Los Angeles La Hnscc in Chicago La Hnscc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease